Introduction Given an enhanced understanding of the biological basis for oncogenesis and the benefit of immunotherapy approaches such as Genentech/Roche's Rituxan, it is no surprise that targeted treatments and immunotherapy dominate the pipeline. Integrating these novel technologies into existing treatment paradigms and demonstrating the 'value' of these high cost treatments will provide major challenges.
Scope
Overview of hematological malignancy market including patient segmentation, unmet needs and how novel therapies will alter existing treatment patterns
Profiles of key agents in late stage development including cytotoxics, immunotherapies and targeted treatments
Analysis of trial data, marketing factors and sales forecasts for key technologies in late-stage clinical development
Clinical, regulatory and pharmacoeconomic challenges and strategies for commercialization
Highlights Targeted therapies dominate the pipeline, constituting 47% of drugs in clinical development. The signal transduction inhibitors (STIs) dominate the MTT class. Focusing on STIs offers developers the potential to target drivers of oncogenesis that may exhibit commonality across a spectrum of hematological malignancies.
Of the drugs in late-stage clinical development, Datamonitor is of the opinion that Chiron's Proleukin and MGI Pharma/ Supergen's Dacogen hold the greatest commercial potential with estimated peak sales by 2014 of $200m and $500m respectively
While there is much hype surrounding the use of the MTTs for the pharmacotherapy of hematological malignancies, the cytostatic nature of some of these agents mean that it is likely that significant tumor regressions will more frequently be seen in context of combinatorial therapy employing traditional cytotoxic drugs.
Reasons to Purchase
Understand unmet needs in the hematological malignancy market based on opinion leader comments regarding both currently marketed and pipeline products
Gain a greater understanding how future economic and regulatory constraints may affect approval for hematological malignancy drugs
Assess the global sales forecasts of late-stage pipeline drugs for hematological malignancies and examine their clinical and commercial potential
(0 items)
